Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19

Blood Adv. 2020 Oct 13;4(19):4864-4868. doi: 10.1182/bloodadvances.2020002595.

Tim Luetkens^{1

2}, Ryan Metcalf^{3

4}, Vicente Planelles³, Yue Zheng³, Erin T Larragoite³, Emily S Spivak⁵, Adam M Spivak⁵, Mary Steinbach¹, Robert C Blaylock^{3

4}, Stephanie V Avila¹, Kim G Hankey², Thomas B Martins^{3

4}, Patricia R Slev^{3

4}, Heather D Mannuel^{6

7}, Mohammad Sajadi⁸, Aaron P Rapoport², Djordje Atanackovic^{1

2}

¹ Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
² Blood and Marrow Transplantation Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD.
³ Department of Pathology, University of Utah, Salt Lake City, UT.
⁴ ARUP Laboratories, Salt Lake City, UT.
⁵ Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT.
⁶ Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD.
⁷ Baltimore Veterans Affairs Medical Center, Baltimore, MD; and.
⁸ Institute of Human Virology, University of Maryland, Baltimore, MD.

Abstract

A severely immunocompromised patient with MM and COVID19 who received a convalescent plasma product showed SARS-CoV-2 clearance.
The convalescent plasma showed humoral immunity against all structural SARS-CoV-2 proteins, which was successfully transferred to the patient.